News

AMERICA STEM CELL, INC. RECEIVES FDA CLEARANCE FOR ITS MULTI-CENTER NATIONWIDE TRIAL

AMERICA STEM CELL, INC. RECEIVES FDA CLEARANCE FOR ITS MULTI-CENTER NATIONWIDE TRIAL

San Antonio, TX  SEPTEMBER 4, 2012. America Stem Cell, Inc. (ASC) announced today it has received clearance from FDA for its Phase I/IIa nationwide multi-center dual-umbilical cord transplantation study evaluating ASC-101 in in patients with hematologic malignancies and myelodysplastic syndrome.

ASC-101 is currently undergoing evaluation in a single-center study at The University of Texas MD Anderson Cancer.  To date, 12 patients have been enrolled in the study with 9 patients evaluable.  On the basis of data obtained in the single-center study, FDA has given approval to proceed with a […]

AMERICA STEM CELL, INC. initiates a Phase I/II trial of ASC-101 in patients with hematologic malignancies undergoing dual-cord transplantation

AMERICA STEM CELL, INC. initiates a Phase I/II trial of ASC-101 in patients with hematologic malignancies undergoing dual-cord transplantation

Novel enzyme technology to enhance stem cell homing and engraftment for improved clinical outcomes for cancer patients

San Antonio, TX, August 27, 2012. America Stem Cell, Inc. announced today the initiation of a single-center study at The University of Texas MD Anderson Cancer Center evaluating ASC-101 in dual-umbilical cord transplantation in patients with hematologic malignancies.

“There is a significant unmet medical need to improve stem cell engraftment into bone marrow for patients undergoing umbilical cord transplantation, and America Stem Cell is committed to […]

Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγnull (NSG) mice.

Robinson SN, Simmons PJ, Thomas MW, Brouard N, Javni JA, Trilok S, Shim J, Yang H, Steiner D, Decker WK, Xing D, Shultz LD, Savoldo B, Dotti G, Bollard DM, Miller L, Champlin RE, Shpall EJ and Zweidler-McKay PA. Ex vivo fucosylation improves human cord blood engraftment in NOD-SCID IL-2Rγnull (NSG) mice. Exp Hematol. 2012 Jun;40(6):445-56. doi: 10.1016/j.exphem.2012.01.015. Epub 2012 Feb 2.

America Stem Cell, Inc. Receives Orphan Drug Designation For ASC-101

Novel enabling technology to enhance stem cell treatments for cancer patients

Orphan designation provides seven–year post approval marketing exclusivity, tax credits, and elimination of FDA prescription drug user fees

SAN ANTONIO, Mar. 29, 2011.

America Stem Cell, Inc. announced today that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to ASC-101 to improve homing to bone marrow (treatment of myeloablation) in patients receiving hematopoietic stem cell transplantation.

“The orphan drug status confirms the importance of this new novel treatment approach to improve outcomes for patients with serious, life-threatening cancers and other disorders for which hematopoietic stem cell transplant […]

America Stem Cell Inc Awarded “Most Promising Life Science Technology Company” at Rice Alliance Life Science Venture Forum

HOUSTON – September 3, 2010

America Stem Cell Inc, was named the ‘Most Promising’ Life Science company at the 9th Annual Rice Alliance for Technology & Entrepreneurship Life Science Venture Forum in Houston last week. Life Science companies showcased their new ventures for an audience of more than 400 attendees, including investors, venture capitalists, industry representatives, business leaders, advisors/mentors, service providers, and entrepreneurs.

Cynthia A. Doerr, M.D., partner, Essex Woodlands Health Ventures said of the presenters, “This is one of the most mature groups of healthcare-related company presentations that I have reviewed in Houston, and I intend to follow their progress […]

DARA BioSciences and America Stem Cell Broaden Collaboration

DARA BioSciences and America Stem Cell Broaden Collaboration

Florida Biologix® Announces Manufacturing Agreement with America Stem Cell Inc.

Alachua, FL: America Stem Cell and Florida Biologix team up to get an important cancer therapy to the clinic that can potentially making a life-changing difference for patients with blood-related cancers such as Leukemia, Lymphoma and Myeloma.
Florida Biologix is pleased to announce that they have signed a development and manufacturing contract for a Phase I cell therapy product, ASC-101, with America Stem Cell. ASC-101 is a breakthrough human recombinant enzyme technology that increases the efficiency of engraftment in transplantation of cord blood derived stem cells. Exciting in vitro and in vivo experimental results attest to the potential for ASC-101 […]

America Stem Cell, Inc. Awarded $2.5 Million from the Texas Emerging Technology Fund

SAN ANTONIO, TX, JULY 15, 2009 11:00 A.M. (CST).

America Stem Cell, Inc. (ASC)
www.americastemcell.com announced today that the company has been awarded $2.5 million
from the State of Texas Emerging Technology Fund (“ETF”) www.emergingtechfund.com.
This investment will enable ASC to accelerate the development of its breakthrough enzyme
technology to enhance the homing and engraftment of cord blood stem cells, and achieve
improved clinical outcomes for cancer patients receiving these stem cell transplants. ASC’s
enzyme treatment could potentially transform cord blood stem cell engraftment, accelerate
patients’ immune system and platelet recovery, reduce opportunistic infections and improve
cord blood stem cell transplant patient survival and quality of life. […]

Stem Cell Enabling Technologies Unveiled at Cord Blood Transplantation Meeting in LA

Stem Cell Enabling Technologies Unveiled at Cord Blood Transplantation Meeting in LA

Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow

Xia L, McDaniel JM, Yago T, Doeden A, McEver RP. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood. 2004 Nov 15;104(10):3091-6. Epub 2004 Jul 27.